Evotec opens new state-of-the-art biology facility on Dorothy Crowfoot Hodgkin Campus

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today celebrated the Grand Opening of a new facility, Building 95 (“B95”), on the Company’s Dorothy Crowfoot Hodgkin Campus at Milton Park. Evotec has had a presence in Abingdon since the Company’s acquisition of Oxford Asymmetry International plc (“OAI”) in 2000 and today is one of the largest occupiers at Milton Park.

Evotec has developed B95 to accommodate new state-of-the-art biology laboratories, a range of collaborative workspaces and meeting rooms as well as a restaurant for employees. The B95 facility was designed with a particular focus on sustainability, and incorporates air source heat pumps, a demand-based laboratory ventilation system, as well as low energy lighting and appliances. These measures will support Evotec in achieving the company’s carbon neutral targets.

George Freeman MP, Minister of State at the Department for Science, Innovation and Technology said: “The opening of these state-of-the-art new labs is further evidence of the strength of the UK’s £ 94 bn life sciences sector, which adds to the 280,000 jobs the industry already supports nationwide and attracts private investment into local economies. The Oxfordshire cluster is one of the crown jewels of our science and innovation community. The work taking place here will ensure the UK continues to blaze a trail from drug discovery and scale-up all the way through to manufacturing, ultimately delivering new therapies that will transform countless lives, while driving economic growth for the UK.”

Professor Steve Davies, Emeritus Professor at the University of Oxford and academic founder of OAI, unveiled a plaque commemorating the event. The ceremony was also attended by Elizabeth Hodgkin, daughter of British Nobel Prize winning chemist Dorothy Crowfoot Hodgkin, after whom Evotec’s campus in Abingdon is named.

Dr Werner Lanthaler, Chief Executive Officer of Evotec SE, commented: “Dorothy Crowfoot Hodgkin Campus is one of Evotec’s fastest-growing fully integrated research and development centres. Building on the early success of OAI, most notably under leadership of Dr Mario Polywka, the site has been pivotal for Evotec’s success as a whole. Mario was a founding chemist of OAI who became the company’s CEO, and subsequently served for many years as Evotec’s COO and Abingdon Site Head. We are grateful that he continues to remain a member of our Supervisory Board to this day.”

Dr Adam Stoten, SVP Academic Partnerships and Head of Evotec’s Abingdon site, commented: “Opening B95 enables us to grow further our business sustainably and we are grateful to our friends and partners who celebrated this milestone together with us today. I would like to express particular gratitude to those who built OAI’s and then Evotec’s presence on the Milton Park site.”

More news and updates 

Hartmut van Lengerich appointed as Chairman of Moa Technology

With over 30 years’ experience in global strategic and operational roles, including serving as Bayer Crop Science’s CEO for Canada, Global Head of Cereals, Head of Fungicides and, most recently, SVP Global Crop Protection Asset Management at Bayer AG, overseeing $13bn in worldwide sales

ACROBiosystems launches the world’s first GMP-grade DLL-4 Protein

ACROBiosystems, a global cornerstone of the pharmaceutical industry committed to offering innovative tools and solutions, announces the launch of GMP grade DLL4. GMP grade DLL4 is the first recombinant Delta-like Ligand 4, or DLL4, to be launched on the market under GMP conditions.

Investors-in-residence join Cancer Research Horizons to advance Ventures team

Jonathan Tobin, a partner at life science venture capital firm Brandon Capital, and Genghis Lloyd-Harris, a senior advisor at life sciences investment firm, Abingworth, have joined Cancer Research Horizons’ Ventures team as advisory investors-in-residence.

Milner, AstraZeneca, and MRC partner for functional genomics advancements

The University of Cambridge announced a new partnership with AstraZeneca and the Medical Research Council (MRC) that will establish a new state-of-the-art functional genomics laboratory at the Milner Therapeutics Institute.

RoslinCT to manufacture world’s-first CRISPR-based therapy

RoslinCT to manufacture exagamglogene autotemcel (exa-cel) for Vertex Pharmaceuticals Inc following an extensive development collaboration

Rosalind Franklin Institute appoints Professor Paul Matthews as new director

The Rosalind Franklin Institute announces Professor Paul Matthews as its new Institute Director. Professor Matthews is a world class clinician scientist with over 30 years of experience working on neurodegenerative disorders.

Brainomix expands to the US with FDA-cleared Stroke AI Platform

Brainomix, the AI-powered medtech solutions company, has heralded its continued US expansion with the launch of its full suite of FDA-cleared modules in its Brainomix 360 platform for stroke care.

Cancer Research Horizons opens nominations for its Innovation & Entrepreneurship Awards 2024

Cancer Research Horizons, the innovation arm of Cancer Research UK, has opened nominations for its Innovation & Entrepreneurship Awards 2024, which celebrate the UK’s most enterprising efforts in oncology.

Merit reaches key project milestone for Moderna's clinical laboratories

Northumberland-headquartered Merit, the UK’s leading industrialised construction and digital manufacturing specialist, has reached a significant project milestone for Moderna’s clinical laboratories project.

PrecisionLife announces new appointments to launch diagnostics and healthcare strategy

PrecisionLife® announces the appointment of Dr Gerald Dunstan as SVP Corporate Development and Hannah Bibby as Product Strategy Lead to drive the company’s expansion into precision diagnostics and personalized healthcare.


More within